Adavosertib

Generic Name: Adavosertib

Brand Names: -

Drug Type: Small Molecule

Chemical Formula: C_₂₇H_₃₂N_₈O_₂

CAS Number: 955365-80-7

Unique Ingredient Identifier: K2T6HJX3I3

Background: MK-1775 has been used in trials studying the treatment of LYMPHOMA, Neoplasms, Ovarian Cancer, Tongue Carcinoma, and Adult Glioblastoma, among others.

Associated Conditions: -

Associated Therapies: -

Clinical Trials

Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia
Previously Treated Myelodysplastic Syndrome
Recurrent Adult Acute Myeloid Leukemia
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Secondary Acute Myeloid Leukemia
Therapy-Related Acute Myeloid Leukemia
Myelodysplastic Syndrome
Untreated Adult Acute Myeloid Leukemia
Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Interventions: Drug: Adavosertib
Drug: Belinostat
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

First Posted Date: 2015-03-06

Last Posted Date: 2018-05-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 20

Registration Number: NCT02381548

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, United States

Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours

Phase 1

Completed

Conditions: Advanced Solid Tumours

Interventions: Drug: Paclitaxel
Drug: AZD1775
Drug: carboplatin

First Posted Date: 2015-01-19

Last Posted Date: 2019-03-25

Lead Sponsor: AstraZeneca

Target Recruit Count: 19

Registration Number: NCT02341456

Locations: 🇰🇷
Research Site, Seoul, Korea, Republic of

Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Phase 2

Completed

Conditions: Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation

Interventions: Drug: Adavosertib
Drug: PLD
Drug: Gemcitabine
Drug: Paclitaxel
Drug: Carboplatin

First Posted Date: 2014-10-23

Last Posted Date: 2023-10-03

Lead Sponsor: AstraZeneca

Target Recruit Count: 95

Registration Number: NCT02272790

Locations: 🇳🇱
Research Site, Amsterdam, Netherlands

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase 1

Completed

Conditions: Metastatic Pancreatic Adenocarcinoma
Stage III Pancreatic Cancer AJCC v6 and v7
Stage IV Pancreatic Cancer AJCC v6 and v7
Unresectable Pancreatic Carcinoma

Interventions: Drug: AZD1775
Drug: Gemcitabine
Drug: Nab-paclitaxel

First Posted Date: 2014-07-18

Last Posted Date: 2023-04-25

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT02194829

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Pennsylvania/Abramson Cancer Center, Philadelphia, Pennsylvania, United States

and more 2 locations

Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2

Active, not recruiting

Conditions: Ovarian Carcinosarcoma
Ovarian Endometrioid Adenocarcinoma
Ovarian Serous Surface Papillary Adenocarcinoma
Ovarian Undifferentiated Carcinoma
Recurrent Fallopian Tube Carcinoma
Recurrent Primary Peritoneal Carcinoma
Ovarian Brenner Tumor
Ovarian Clear Cell Cystadenocarcinoma
Recurrent Ovarian Carcinoma
Ovarian Mucinous Cystadenocarcinoma

Interventions: Drug: Adavosertib
Drug: Gemcitabine Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Other: Placebo Administration
Other: Questionnaire Administration

First Posted Date: 2014-04-02

Last Posted Date: 2024-07-24

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 124

Registration Number: NCT02101775

Locations: 🇨🇦
University Health Network Princess Margaret Cancer Center P2C, Toronto, Ontario, Canada
🇺🇸
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇨🇦
BCCA-Cancer Centre for the Southern Interior, Kelowna, British Columbia, Canada

and more 13 locations

Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Phase 1

Completed

Conditions: Primary Central Nervous System Neoplasm
Recurrent Rhabdomyosarcoma
Refractory Malignant Solid Neoplasm
Central Nervous System Ganglioneuroblastoma
Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
Recurrent Childhood Central Nervous System Embryonal Neoplasm
Pineoblastoma
Refractory Medulloblastoma
Refractory Neuroblastoma
Central Nervous System Embryonal Tumor With Rhabdoid Features

Interventions: Drug: Adavosertib
Drug: Irinotecan Hydrochloride

First Posted Date: 2014-03-24

Last Posted Date: 2023-09-26

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 76

Registration Number: NCT02095132

Locations: 🇺🇸
C S Mott Children's Hospital, Ann Arbor, Michigan, United States
🇺🇸
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States
🇺🇸
Children's Hospital of Wisconsin, Milwaukee, Wisconsin, United States

and more 21 locations

Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer

Phase 2

Terminated

Conditions: Previously Untreated Stage IV Non-Squamous Non Small Cell Lung Cancer

Interventions: Drug: AZD1775
Drug: AZD1775 Matching Placebo
Drug: pemetrexed
Drug: carboplatin

First Posted Date: 2014-03-14

Last Posted Date: 2017-03-29

Lead Sponsor: AstraZeneca

Target Recruit Count: 22

Registration Number: NCT02087241

Locations: 🇺🇸
Research Site, Nashville, Tennessee, United States

A Placebo Controlled Study Comparing AZD1775+ Docetaxel Versus Placebo+Docetaxel to Treat Lung Cancer

Phase 2

Terminated

Conditions: Previously Treated Non Small Cell Lung Cancer

Interventions: Drug: AZD1775 Placebo
Drug: AZD1775
Drug: Antimitotic Agent
Drug: pegfiligrastim

First Posted Date: 2014-03-14

Last Posted Date: 2016-06-14

Lead Sponsor: AstraZeneca

Target Recruit Count: 48

Registration Number: NCT02087176

Locations: 🇺🇸
Research Site, Milwaukee, Wisconsin, United States

Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas

Phase 1

Completed

Conditions: Anaplastic Astrocytoma
Anaplastic Oligoastrocytoma
Diffuse Intrinsic Pontine Glioma
Diffuse Midline Glioma, H3 K27M-Mutant
Gliosarcoma
Glioblastoma

Interventions: Drug: Adavosertib
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Radiation: Radiation Therapy

First Posted Date: 2013-08-14

Last Posted Date: 2024-01-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 46

Registration Number: NCT01922076

Locations: 🇺🇸
Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, United States
🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States

and more 21 locations

Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma

Phase 1

Active, not recruiting

Conditions: Glioblastoma
Recurrent Glioblastoma

Interventions: Drug: Adavosertib
Radiation: Radiation Therapy
Drug: Temozolomide

First Posted Date: 2013-05-08

Last Posted Date: 2024-07-03

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 74

Registration Number: NCT01849146

Locations: 🇺🇸
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States

and more 9 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy